• News

Etrasimod Significantly Improves Atopic Dermatitis in Phase 2b Trial

  • Healio
  • New York, NY
  • (April 24, 2021)

Etrasimod, an investigational drug for moderate to severe atopic dermatitis, demonstrated statistically significant improvements in a phase 2b clinical trial, according to a study presented at AAD VMX 2021.

Learn more